In-article:

Biophytis provides an update on the development of Sarconeos (BIO101) in Covid-19 at the 4th Annual Longevity Therapeutics Summit Results of the COVA phase 2-3 study expected in the 3rd quarter of 2022 – 07/04/2022 at 08:00


Paris, France, Cambridge (Massachusetts, USA), July 4, 2022 – 8:00 a.m. – Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a stage clinic specializing in the development of treatments that aim to slow the degenerative processes associated with aging and improve the functional results of patients suffering from age-related diseases, announces today that its CEO, Stanislas Veillet, PhD, has given a presentation at the 4th Annual Longevity Therapeutics Summit in San Francisco.

Biophytis’ presentation entitled “Discussing the Use of Sarconeos (BIO101) for the Treatment of an Emerging Age-Related Disease, Covid-19”, revolved around the description of the mechanism of action of Sarconeos (BIO101), its interest in the treatment of age-related diseases such as sarcopenia, and provided an update on the progress of the COVA phase 2-3 study in Covid-19.



Source link -86